Form 4: Ionis Pharmaceuticals CEO Brett P. Monia Acquires Additional Shares Under Employee Stock Purchase Plan

Brett P. Monia, CEO of Ionis Pharmaceuticals, reports the acquisition of 437 shares of common stock through the company's employee stock purchase plan.

Summary

• On February 28, 2025, Brett P. Monia, the Chief Executive Officer of Ionis Pharmaceuticals, acquired 437 shares of Ionis Pharmaceuticals common stock.
• The shares were purchased under the Amended and Restated 2000 Employee Stock Purchase Plan at a price of $28.2115 per share.
• Following the transaction, Monia directly owns 181,120 shares of Ionis Pharmaceuticals common stock.
• These shares cannot be sold until August 28, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The CEO's participation in the employee stock purchase plan suggests confidence in the company, but it's a routine transaction.

Positives

• The CEO's participation in the employee stock purchase plan demonstrates confidence in the company's future.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock ownership is a common practice in publicly traded companies, including pharmaceutical firms like Biogen, Alnylam Pharmaceuticals, and Vertex Pharmaceuticals.
• These companies also have employee stock purchase plans and equity-based compensation for their executives.
• The level of stock ownership and the terms of the purchase plan are generally in line with industry standards for companies of similar size and market capitalization.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals management's confidence in the company's prospects.

Key Dates